Performance and Head-to-Head Comparison of Three Clinical Models to Predict Occurrence of Postthrombotic Syndrome: A Validation Study

Abstract

Objective The SOX-PTS, Amin, and Méan models are three different clinical prediction scores stratifying the risk for postthrombotic syndrome (PTS) development in patients with acute deep vein thrombosis (DVT) of the lower limbs. Herein, we aimed to assess and compare these scores in the same cohort of patients.

Methods We retrospectively applied the three scores in a cohort of 181 patients (196 limbs) who participated in the SAVER pilot trial for an acute DVT. Patients were stratified into PTS risk groups using positivity thresholds for high-risk patients as proposed in the derivation studies. All patients were assessed for PTS 6 months after index DVT using the Villalta scale. We calculated the predictive accuracy for PTS and area under receiver operating characteristic (AUROC) curve for each model.

Results The Méan model was the most sensitive (sensitivity 87.7%; 95% confidence interval [CI]: 77.2–94.5) with the highest negative predictive value (87.5%; 95% CI: 76.8–94.4) for PTS. The SOX-PTS was the most specific score (specificity 97.5%; 95% CI: 92.7–99.5) with the highest positive predictive value (72.7%; 95% CI: 39.0–94.0). The SOX-PTS and Méan models performed well for PTS prediction (AUROC: 0.72; 95% CI: 0.65–0.80 and 0.74; 95% CI: 0.67–0.82), whereas the Amin model did not (AUROC: 0.58; 95% CI: 0.49–0.67).

Conclusion Our data support that the SOX-PTS and Méan models have good accuracy to stratify the risk for PTS.

Keywords

deep vein thrombosis - postthrombotic syndrome - prediction rules

^* Deceased

Publication History

Received: 22 November 2022

Accepted: 17 February 2023

Accepted Manuscript online:
21 February 2023

Article published online:
24 March 2023

• References

• 1 Kahn SR. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. The post-thrombotic syndrome. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 413-418
• 2 Rabinovich A, Kahn SR. How I treat the postthrombotic syndrome. Blood 2018; 131 (20) 2215-2222
• 3 Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 1997; 126 (06) 454-457
• 4 Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol 1994; 31 (01) 49-53
• 5 Makedonov I, Kahn SR, Galanaud JP. Prevention and management of the post-thrombotic syndrome. J Clin Med 2020; 9 (04) 923
• 6 Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011; 124 (08) 756-765
• 7 Thukral S, Salter A, Lancia S, Kahn SR, Vedantham S. Predictors of clinical outcomes of pharmacomechanical catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: analysis of a multicenter randomized trial. J Vasc Interv Radiol 2022; 33 (10) 1161-1170.e11
• 8 Amin EE, van Kuijk SMJ, Joore MA, Prandoni P, Ten Cate H, Ten Cate-Hoek AJ. Development and validation of a practical two-step prediction model and clinical risk score for post-thrombotic syndrome. Thromb Haemost 2018; 118 (07) 1242-1249
• 9 Méan M, Limacher A, Alatri A, Aujesky D, Mazzolai L. Derivation and validation of a prediction model for risk stratification of post-thrombotic syndrome in elderly patients with a first deep vein thrombosis. Thromb Haemost 2018; 118 (08) 1419-1427
• 10 Rabinovich A, Ducruet T, Kahn SR. SOX Trial investigators. Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis. J Thromb Haemost 2018; 16 (02) 262-270
• 11 Delluc A, Ghanima W, Kovacs MJ. et al. Statins for venous event reduction in patients with venous thromboembolism: a multicenter randomized controlled pilot trial assessing feasibility. J Thromb Haemost 2022; 20 (01) 126-132
• 12 Rabinovich A, Gu CS, Vedantham S. et al; ATTRACT Trial Investigators. External validation of the SOX-PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis. J Thromb Haemost 2020; 18 (06) 1381-1389
• 13 Rinfret F, Gu CS, Vedantham S, Kahn SR. New and known predictors of the postthrombotic syndrome: a subanalysis of the ATTRACT trial. Res Pract Thromb Haemost 2022; 6 (06) e12796
• 14 Zhang J, Ma F, Yao J. et al. Development and validation of a clinical prediction model for post thrombotic syndrome following anticoagulant therapy for acute deep venous thrombosis. Thromb Res 2022; 214: 68-75
• 15 Yu T, Shen R, You G. et al. Machine learning-based prediction of the post-thrombotic syndrome: model development and validation study. Front Cardiovasc Med 2022; 9: 990788
• 16 Delluc A, Ghanima W, Kovacs MJ. et al. Prevention of post-thrombotic syndrome with rosuvastatin: a multicenter randomized controlled pilot trial (SAVER). Thromb Res 2022; 213: 119-124